Key terms
About TWST
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TWST news
Mar 25
8:17pm ET
Cathie Wood’s ARK Investment bought 129K shares of Twist Bioscience today
Mar 21
2:37am ET
Buy Rating Justified: Twist Bioscience’s Strong Demand and Strategic Expansion Signal Market Share Growth
Mar 05
1:23am ET
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
Feb 08
4:41am ET
Twist Bioscience Shareholders Elect Directors, Approve Compensation
Feb 07
10:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Walgreens Boots Alliance (WBA) and Twist Bioscience (TWST)
Feb 06
8:19am ET
Twist Bioscience and Element Biosciences team on Exome sequencing solutions
Feb 06
8:16am ET
Twist debuts cfDNA library preparation kit for liquid biopsy applications
Feb 06
3:35am ET
Buy Rating for Twist Bioscience on Strong Financial Performance and Positive Business Outlook
Feb 05
7:50am ET
Analysts’ Top Healthcare Picks: Premier (PINC), Twist Bioscience (TWST)
Feb 05
7:31am ET
Twist Bioscience price target raised to $43 from $30 at Scotiabank
Feb 05
6:49am ET
Twist Bioscience price target raised to $38 from $27 at Baird
Feb 05
2:56am ET
Twist Bioscience (TWST) Gets a Buy from Barclays
Feb 03
1:09pm ET
Twist Bioscience price target raised to $25 from $19 at JPMorgan
Feb 03
12:48pm ET
Maintaining Sell Rating on Twist Bioscience Amid Revenue Outperformance and Uncertain Margin Targets
Feb 02
11:35am ET
Twist Bioscience: A Strong Buy on Surpassing Financials and Growth Potential
Feb 02
7:43am ET
Twist Bioscience sees Q2 revenue $70M-$71M, consensus $70.09M
Feb 02
7:41am ET
Twist Bioscience raises FY24 revenue view to $288M-$293M from $285M-$290M
Feb 02
7:36am ET
Twist Bioscience reports Q1 EPS (75c), consensus (78c)
Feb 02
7:05am ET
Options Volatility and Implied Earnings Moves Today, February 02, 2024
Jan 24
8:17am ET
Twist Bioscience expands express genes rapid synthesis service
Jan 24
7:20am ET
Twist Bioscience price target raised to $45 from $30 at Barclays
Jan 17
4:48am ET
Twist Bioscience upgraded to Buy from Neutral at Goldman Sachs
Jan 05
11:35am ET
Twist Bioscience: A Strong Buy on Robust Portfolio and Market Leadership with Upside Potential
Jan 05
8:12am ET
Twist Bioscience appoints Adam Laponis as chief financial officer
No recent news articles are available for TWST
No recent press releases are available for TWST
TWST Financials
Key terms
Ad Feedback
TWST Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TWST Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range